Accordingly, in a further aspect, the present invention provides for the use of neutralizing antibodies raised against GPR40 in therapy. [0107] Compounds which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and, lozenges.